Salarius Pharmaceuticals, Inc.
Peptide conjugate therapeutics—engineered peptides linked to functional payloads for targeted drug delivery
- Sector
- Biotech
- Headquarters
- Houston, TX
- Founded
- 2014
- Latest Form D
- $10M offered, Dec 2024
- Total capital
- $24.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $24.6M
- 4 Form D · last Dec 2024
- 22 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 9 pending · first 2023
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Offering registeredForm D · SEC · 4th filing$10M
- Private capital raisedForm D · SEC · 3rd filing$6M
- Private capital raisedForm D · SEC · 2nd filing$2.3M
- Private capital raisedForm D · SEC · 1st filing$16.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Arnold C. HanishDirectorNamed in SEC Form D filings
- Bruce J. McCreedyDirectorNamed in SEC Form D filings
- David J. ArthurExecutive OfficerNamed in SEC Form D filings
- David BearssDirector, PromoterNamed in SEC Form D filings
- Jonathan C. LieberDirectorNamed in SEC Form D filings
- Jonathan NorthrupDirector, PromoterNamed in SEC Form D filings
Show all 11 people
- Mark J. RosenblumExecutive OfficerNamed in SEC Form D filings
- Paul C. LammersDirectorNamed in SEC Form D filings
- Sunil J. SharmaExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Tess J. BurlesonDirectorNamed in SEC Form D filings
- William J. McVicarDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 10- Pending3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameUSPTOApplication 19020999
- GrantedDeuterium-enriched Isoindolinonyl-azepanediones And Related Compounds And Methods Of Treating Medical Disorders Using SameUSPTOUS 11,773,080
- PendingMethods Of Use Of Deuterium-enriched CompoundsUSPTOApplication PCTUS2024024915
Show all 10 patent records
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameDec 18, 2025 · Application 19020999Pending
- Deuterium-enriched Isoindolinonyl-azepanediones And Related Compounds And Methods Of Treating Medical Disorders Using SameOct 3, 2023 · US 11,773,080Granted
- Methods Of Use Of Deuterium-enriched CompoundsApplication PCTUS2024024915Pending
- Solid Forms And Methods Of UseApplication PCTUS2024010321Pending
- Methods Of Use Of Deuterium-enriched CompoundsApplication PCTUS2023080129Pending
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameApplication 18378896Pending
- Solid Forms And Methods Of UseApplication 63437527Pending
- Methods Of Use Of Deuterium-enriched CompoundsApplication 63425898Pending
- Solid Forms And Method Of UseApplication 19145876Pending
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameApplication 18674347Pending
Related companies, and why
- Indi Molecular, Inc.Similar federal contract value in Biotech · null in contracts
- Annovis Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Cyrano Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cellino Biotech IncSimilar federal contract value in Biotech · null in contracts
- Keros TherapeuticsSimilar federal contract value in Biotech · null in contracts
- TheraCea Pharma LCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .